Skip to content
Clinical Trials – home
Not yet recruiting

Safety and Efficacy of LIB-01 Monohydrate in Healthy Adults and Men with Erectile Dysfunction: A Randomized, Double‑Blind, Placebo‑Controlled Phase 2b Study

Verified siteFast replyInvestigational
Clinical Trials Concierge

Prefer not to search on your own, or looking for clinical trials for a rare disease?

What is this trial about?

A plain-language summary of the goals, design and what participants do

The study focuses on erectile dysfunction, a condition in which a man has difficulty achieving or maintaining an erection suitable for sexual activity. The treatment being tested is an oral tablet called LIB-01, which is taken by mouth as a powder that is mixed with liquid to form a suspension. A matching placebo tablet, which looks the same but does not contain the active ingredient, is also used for comparison.

The purpose of the trial is to learn whether repeated daily doses of LIB-01 are safe and can improve erection quality. First, a small group of healthy adults will receive the medication or placebo to assess safety. After this safety check, men with erectile dysfunction will be enrolled and will take the study tablets each day for about three months while researchers collect information on side effects, blood pressure, heart rate, and routine lab tests. Participants also complete a simple questionnaire that asks about the ability to have satisfactory erections.

During the study, participants visit the clinic several times for brief examinations and to answer the questionnaire. Researchers will monitor for any unwanted effects, such as dizziness or changes in vital signs, and will record any serious problems. Blood samples may be taken to check how the drug is processed in the body, but no detailed medical procedures are required beyond standard safety checks.

The research process

The trial runs in 7 steps – from screening to follow-up. Each step says what happens and what the team monitors.

  1. Step 1

    Baseline Assessments

    After joining the study you will undergo a series of baseline examinations to record your health status before receiving any medication.

    These examinations include measurements of blood pressure, heart rate, breathing rate, and body temperature, a 12‑lead electrocardiogram (ECG) that records the electrical activity of the heart, a physical examination, and laboratory tests of blood and urine.

    You will also complete questionnaires that assess sexual function, including the International Index of Erectile Function (IIEF‑EF) and the Sexual Encounter Profile (SEP) questions, as well as a Global Assessment Question (GAQ) about overall sexual satisfaction.

  2. Step 2

    Randomization and Medication Assignment

    Based on the baseline information you will be randomly assigned to receive either the active drug lib‑01 monohydrate or a matching placebo tablet that looks identical but contains no active ingredient.

    The random assignment ensures that the study can compare the effects of the active drug with those of the inactive tablet without bias.

  3. Step 3

    First Dose and Day‑1 Safety Checks

    On the first day you will take one oral dose of the assigned tablet, which contains 100 mg of lib‑01 monohydrate if you are in the active group, or a matching placebo if you are in the control group.

    The tablet is taken with water, preferably in the morning, and you will be asked to fast for at least two hours before and after taking the dose.

    Blood samples will be drawn a few hours after the dose to measure how much drug is in your bloodstream (pharmacokinetic or PK parameters such as AUC, Cmax, and Tmax).

    Vital signs and a short ECG will be repeated to ensure there are no immediate safety concerns.

  4. Step 4

    Day‑3 Follow‑up Assessments

    Three days after the first dose you will return for additional safety assessments.

    Further blood samples will be collected to evaluate drug accumulation and additional PK measurements, including trough levels and half‑life.

    Your blood pressure, heart rate, and ECG will be checked again, and any side effects you have experienced will be recorded.

  5. Step 5

    Daily Medication Routine

    You will continue to take one tablet each day for a total treatment period of 12 weeks (approximately 84 days).

    The tablet should be swallowed whole with water and taken at the same time each day to maintain consistent drug levels.

    If you are assigned to the placebo group you will follow the identical schedule with the inactive tablet.

  6. Step 6

    Scheduled Clinic Visits

    You will attend clinic visits at Week 4 (Day 29), Week 8 (Day 57), Week 12 (Day 85), and Week 16 (Day 113).

    During each visit vital signs, ECG, and laboratory tests will be repeated to monitor safety.

    You will complete the IIEF‑EF questionnaire again to assess any changes in erectile function, and you will answer the SEP questions 2 and 3 to record the success of sexual attempts.

    The GAQ will be asked to capture your overall impression of any improvement in erections.

    The Week 12 visit marks the end of the active dosing period; the Week 16 visit is a follow‑up to evaluate lasting effects after the medication has been stopped.

  7. Step 7

    Final Study Completion

    At the final visit you will undergo a comprehensive safety assessment, including vital signs, ECG, and laboratory tests, and you will complete the final set of questionnaires.

    All collected information will be used to compare the safety and effectiveness of lib‑01 monohydrate with the placebo in participants with ED.

    You will be thanked for your participation, and any study‑related findings will be communicated to you in accordance with the study protocol.

Who can join the trial?

8 criteria

  • Be a male participant.
  • For the safety part of the study, be between 18 and 65 years old; for the part that tests the medicine for erectile problems, be between 25 and 70 years old.
  • Weigh at least 50 kilograms (about 110 pounds).
  • Have not used any tobacco (cigarettes, cigars, vaping, etc.) in the three months before joining.
  • Agree to use a condom from the first day of taking the study tablets until two days after the last dose, or to avoid any unprotected sexual activity during that time.
  • If you have erectile dysfunction, have a stable opposite‑sex (heterosexual) relationship that has lasted at least six months.
  • Be willing to be sexually active at least once a week while taking the study medication.
  • Have a low score on a standard questionnaire that measures men’s ability to achieve an erection; a lower score means more difficulty with erections.

Who cannot join the trial?

5 criteria

  • Having any health problem that could interfere with the study or make taking the medication unsafe (a condition that could affect the results or increase risk).
  • Taking medicines or supplements that might interact with the study drug (drugs that could change how the study medication works).
  • Being younger or older than the ages allowed for the trial (outside the required age range).
  • Not being male, since the study only enrolls men.
  • Being unable to understand the study information or give consent (cannot agree to participate knowingly).
Clinical Trials Concierge

Prefer not to search on your own, or looking for clinical trials for a rare disease?

Tell us about your condition – we search every trial in Europe and connect you with the right site.

We usually reply within a few days

Verified sites

All sites with verified contact details – recruitment status may not be available; ask directly

Trial locations

Where you can join this trial

Countries are shaded by recruitment status. Click a recruiting country to ask about joining there.

Not yet recruiting
Not finding your country?

Not sure what to do next?

Joining a clinical trial can seem overwhelming. We guide you step by step, so you know exactly what to expect and how we support you through the process.

See the full process and FAQ

Investigated drugs

Lib-01 monohydrate is an investigational drug that comes as a powder meant to be mixed with water and taken by mouth. In this study participants take the medication once each day. The first part of the trial looks at how safe and well‑tolerated the drug is when healthy adults use it for a short period. The second part tests whether the drug can improve erectile function in men who have erectile dysfunction, comparing the results to those who received a placebo. The medication is being evaluated for both its safety profile and its ability to help with erectile problems.

What is already known about the treatment

LIB-01 monohydrate - The drug is taken by mouth as a powder that is mixed with water to make a drink, and each dose provides 100 mg of the active substance. It is still an experimental medicine being studied in phase 2b trials and is not yet approved for regular use. The medication is being tested to treat erectile dysfunction, a condition where a man has difficulty getting or keeping an erection. It works by enhancing the signals that cause the blood vessels in the penis to widen, which increases blood flow, and it belongs to the class of oral agents that improve blood flow for erectile problems.

Investigated diseases

Erectile dysfunction - Erectile dysfunction is the persistent inability to achieve or maintain a penile erection sufficient for satisfactory sexual activity. It often develops gradually, with men noticing reduced firmness or frequency of erections over months or years. The condition may worsen over time if underlying factors such as vascular changes, hormonal shifts, or nerve damage continue to progress.
Trial detailsLast updated 20 Nov 2026
Age18+ yearsPhasePhase IITrial ID2026-525955-98-00Protocol codeDCT5839Estimated enrolment168 patientsSponsorDicot Pharma AB

sourced from the EU Clinical Trials Register and site verification

Want to learn more about this trial or check if you can participate?

Clinical Trials Concierge

Prefer not to search on your own, or looking for clinical trials for a rare disease?

Tell us about your condition – we search every trial in Europe and connect you with the right site.